Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
In Vivo
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
In Vivo

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Visit iiar on Facebook
  • Follow us on Linkedin

safety

  • Open Access
    Preclinical Safety Assessment of Deferoxamine-preconditioned Canine Adipose Tissue-derived Mesenchymal Stem Cells
    XINPENG JI, JUNFANG ZHANG, SHIYU JIN, HAILONG TENG, YUZE ZHOU, XIANGZI LI, SEONG-HO CHOI and QIANG LI
    In Vivo November 2024, 38 (6) 2645-2655; DOI: https://doi.org/10.21873/invivo.13741
  • Open Access
    Comparison of Misoprostol for Labor Induction: Vaginal Insert Versus Oral Application Concerning Efficiency and Safety
    DOMINIK RATIU, MIRKA HUNKE, JESSIKA RATIU, NINA MALLMANN-GOTTSCHALK, PETER MALLMANN, SUNHWA BAEK, BERTHOLD GRÜTTNER and KATHERINA HIDE-MOSER
    In Vivo September 2024, 38 (5) 2349-2357; DOI: https://doi.org/10.21873/invivo.13701
  • Open Access
    A Prospective Study Regarding the Efficacy and Safety of the BNT162b2 Vaccine in Patients With Solid Malignancies Undergoing Systemic Chemotherapy
    EIKI YAMASAKI, FUKUTARO SHIMAMOTO, HIROKI NISHIKAWA, MASAHIRO GOTO, MITSUHIKO IWAMOTO, KOSEI KIMURA, AKIRA UKIMURA, NAOFUMI OOSAKA, KOHEI TANIGUCHI, FUMIHITO ONO, TETSUJI TERAZAWA, TOSHIFUMI YAMAGUCHI, KEN ASAISHI, TAKAKO IKEGAMI, KAZUHISA UCHIYAMA, SHIRO NAKAMURA and KAZUHIDE HIGUCHI
    In Vivo November 2022, 36 (6) 2780-2789; DOI: https://doi.org/10.21873/invivo.13015
  • You have access
    Safety and Effectiveness of Ixazomib Dose-escalating Strategy in Ixazomib-Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma
    YASUKATA OHASHI, MEGUMI YATABE, DAISUKE NIIJIMA, KENTARO TANI, CHIAKI OGAWA, YUTAKA YACHI, TOSHIYA KAGOO, SAIGEN BOKU, HIRONORI UENO, TAKAHIRO YANO, KOJI HIGAI and AKIHIRO YOKOYAMA
    In Vivo September 2020, 34 (5) 2821-2828; DOI: https://doi.org/10.21873/invivo.12108
  • You have access
    An Open-label, Single-arm Study of CRYO2 for Debulking at the Site of Central Airway Obstruction or Stenosis
    HIDEO SAKA, MASAHIDE OKI, AKIKO KADA and AKIKO M. SAITO
    In Vivo September 2019, 33 (5) 1641-1644; DOI: https://doi.org/10.21873/invivo.11649
  • You have access
    Characteristics and Outcomes of Extreme Elderly Patients With Hepatocellular Carcinoma in South Korea
    JI HO SEO, DONG HYUN KIM, EUNAE CHO, CHUNG HWAN JUN, SEON YOUNG PARK, SUNG BUM CHO, CHANG HWAN PARK, HYUN SOO KIM, SUNG KYU CHOI and JONG SUN REW
    In Vivo January 2019, 33 (1) 145-154; DOI: https://doi.org/10.21873/invivo.11451
In Vivo

© 2026 In Vivo

Powered by HighWire